Calidi Biotherapeutics Shares Plunge After Pricing $2 Million Direct Offering, Private Placement

MT Newswires Live10-24

Calidi Biotherapeutics (CLDI) shares were down 22% in recent trading on Wednesday after the company said it priced a registered direct offering and concurrent private placement.

The biotechnology company said it agreed to sell to certain institutional investors about 2.1 million common shares at $1 apiece in the direct offering.

The concurrent private placement covers the issue of series E warrants to purchase up to 2.1 million shares and series F warrants to purchase up to 2.1 million shares, Calidi said.

Both series warrants have an exercise price of $1.13 per share and can be exercised six months after issue, according to the company. The series E and series F warrants have a term of one year and five years, respectively.

Calidi expects to raise $2 million in gross proceeds from the offering and private placement and plans to use the proceeds for working capital, general corporate purposes, pre-clinical and clinical trials.

The company said it expects to close the offering on or about Thursday.

Price: 0.88, Change: -0.25, Percent Change: -21.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment